COMMUNIQUÉS West-GlobeNewswire

LUKE Named to 10-Year $43B Defense Health Agency IDIQ for the Medical Q-Coded Support and Services-Next Generation Program
03/05/2024
ROCKLEDGE, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- LUKE, a trusted leader in healthcare staffing for the U.S. Government, is proud to announce it has received a 10-year indefinite-delivery/indefinite-quantity (IDIQ) [...]
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
02/05/2024
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
02/05/2024
Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05/2024
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Cellectis nomme Arthur Stril directeur financier par intérim
02/05/2024
NEW YORK, 02 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® [...]
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
02/05/2024
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02/05/2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference
02/05/2024
DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
02/05/2024
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today [...]
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
02/05/2024
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . ( [...]
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
02/05/2024
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. ( [...]
LeMaitre Q1 2024 Financial Results
02/05/2024
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/05/2024
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
02/05/2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. [...]
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
02/05/2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory [...]
Kura Oncology Reports First Quarter 2024 Financial Results
02/05/2024
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data [...]
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
02/05/2024
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage [...]
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
02/05/2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
02/05/2024
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program [...]

Pages